Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group
| Autor: | Stewart, H.J., Forrest, A P, Everington, D, McDonald, C C, Dewar, J A, Hawkins, R A, Prescott, Robin J, George, W D |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 1996 |
| Předmět: | |
| Zdroj: | Stewart, H J, Forrest, A P, Everington, D, McDonald, C C, Dewar, J A, Hawkins, R A, Prescott, R J & George, W D 1996, ' Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group ', British Journal of Cancer, vol. 74, no. 2, pp. 297-9 . < http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074573/ > |
| Popis: | In 1985 a second randomisation was initiated for women in the treatment arm of the Scottish Tamoxifen Trial either to stop tamoxifen at 5 years or to continue indefinitely. A preliminary analysis of outcome in 342 patients at a median follow-up of 6 years suggests that a worthwhile gain in disease control from continuing adjuvant tamoxifen beyond 5 years is unlikely. [Hazard ratio for events (relapse or death without relapse) is 1.27, 95% CI = 0.87 - 1.85.] There is a suggestion that therapy for longer than 5 years may increase the risk of endometrial carcinoma (P = 0.064). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|